Rachel A Freedman1, Christina A Minami2, Eric P Winer1, Monica Morrow3, Alexander K Smith4,5, Louise C Walter4,5, Mina S Sedrak6, Haley Gagnon1, Adriana Perilla-Glen1, Hans Wildiers7, Tanya M Wildes8, Stuart M Lichtman9, Kah Poh Loh10, Etienne G C Brain11, Pamela S Ganschow12, Kelly K Hunt13, Deborah K Mayer14,15, Kathryn J Ruddy16, Reshma Jagsi17,18, Nancy U Lin1, Beverly Canin19, Barbara K LeStage20,21, Anna C Revette22, Mara A Schonberg23, Nancy L Keating24,25. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2. Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Division of Geriatrics, Department of Medicine, University of California, San Francisco, San Francisco. 5. Division of Geriatrics, Veterans Affairs Health Care System, San Francisco, California. 6. Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California. 7. Department of General Medical Oncology and Multidisciplinary Breast Center, University Hospitals Leuven, KU Leuven, Leuven, Belgium. 8. Division of Medical Oncology, Washington University School of Medicine, St Louis, Missouri. 9. Memorial Sloan Kettering Cancer Center, Commack, New York. 10. James P. Wilmot Cancer Institute, Division of Hematology/Oncology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York. 11. Department of Medical Oncology, Institut Curie, Saint-Cloud, France. 12. Department of Medicine, Rush University Medical College and Cook County Health, Chicago, Illinois. 13. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 14. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill. 15. School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill. 16. Department of Oncology, Mayo Clinic, Rochester, Minnesota. 17. Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor. 18. Department of Radiation Oncology, University of Michigan, Ann Arbor. 19. Cancer and Aging Research Group. 20. Dana-Farber Cancer Institute, Boston, Massachusetts. 21. Alliance for Clinical Trials in Oncology, Boston, Massachusetts. 22. Survey and Data Management Core, Dana-Farber Cancer Institute, Boston, Massachusetts. 23. Division of General Medicine, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 24. Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts. 25. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
IMPORTANCE: There is currently no guidance on how to approach surveillance mammography for older breast cancer survivors, particularly when life expectancy is limited. OBJECTIVE: To develop expert consensus guidelines that facilitate tailored decision-making for routine surveillance mammography for breast cancer survivors 75 years or older. EVIDENCE: After a literature review of the risk of ipsilateral and contralateral breast cancer events among breast cancer survivors and the harms and benefits associated with mammography, a multidisciplinary expert panel was convened to develop consensus guidelines on surveillance mammography for breast cancer survivors 75 years or older. Using an iterative consensus-based approach, input from clinician focus groups, and critical review by the International Society for Geriatric Oncology, the guidelines were refined and finalized. FINDINGS: The literature review established a low risk for ipsilateral and contralateral breast cancer events in most older breast cancer survivors and summarized the benefits and harms associated with mammography. Draft mammography guidelines were iteratively evaluated by the expert panel and clinician focus groups, emphasizing a patient's risk for in-breast cancer events, age, life expectancy, and personal preferences. The final consensus guidelines recommend discontinuation of routine mammography for all breast cancer survivors when life expectancy is less than 5 years, including those with a history of high-risk cancers; consideration to discontinue mammography when life expectancy is 5 to 10 years; and continuation of mammography when life expectancy is more than 10 years. Individualized, shared decision-making is encouraged to optimally tailor recommendations after weighing the benefits and harms associated with surveillance mammography and patient preferences. The panel also recommends ongoing clinical breast examinations and diagnostic mammography to evaluate clinical findings and symptoms, with reassurance for patients that these practices will continue. CONCLUSIONS AND RELEVANCE: It is anticipated that these expert guidelines will enhance clinical practice by providing a framework for individualized discussions, facilitating shared decision-making regarding surveillance mammography for breast cancer survivors 75 years or older.
IMPORTANCE: There is currently no guidance on how to approach surveillance mammography for older breast cancer survivors, particularly when life expectancy is limited. OBJECTIVE: To develop expert consensus guidelines that facilitate tailored decision-making for routine surveillance mammography for breast cancer survivors 75 years or older. EVIDENCE: After a literature review of the risk of ipsilateral and contralateral breast cancer events among breast cancer survivors and the harms and benefits associated with mammography, a multidisciplinary expert panel was convened to develop consensus guidelines on surveillance mammography for breast cancer survivors 75 years or older. Using an iterative consensus-based approach, input from clinician focus groups, and critical review by the International Society for Geriatric Oncology, the guidelines were refined and finalized. FINDINGS: The literature review established a low risk for ipsilateral and contralateral breast cancer events in most older breast cancer survivors and summarized the benefits and harms associated with mammography. Draft mammography guidelines were iteratively evaluated by the expert panel and clinician focus groups, emphasizing a patient's risk for in-breast cancer events, age, life expectancy, and personal preferences. The final consensus guidelines recommend discontinuation of routine mammography for all breast cancer survivors when life expectancy is less than 5 years, including those with a history of high-risk cancers; consideration to discontinue mammography when life expectancy is 5 to 10 years; and continuation of mammography when life expectancy is more than 10 years. Individualized, shared decision-making is encouraged to optimally tailor recommendations after weighing the benefits and harms associated with surveillance mammography and patient preferences. The panel also recommends ongoing clinical breast examinations and diagnostic mammography to evaluate clinical findings and symptoms, with reassurance for patients that these practices will continue. CONCLUSIONS AND RELEVANCE: It is anticipated that these expert guidelines will enhance clinical practice by providing a framework for individualized discussions, facilitating shared decision-making regarding surveillance mammography for breast cancer survivors 75 years or older.
Authors: Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-06-11 Impact factor: 508.702
Authors: Rachel A Freedman; Nancy L Keating; Lydia E Pace; Joyce Lii; Ellen P McCarthy; Mara A Schonberg Journal: J Clin Oncol Date: 2017-07-27 Impact factor: 44.544
Authors: Mara A Schonberg; Edward R Marcantonio; Long Ngo; Donglin Li; Rebecca A Silliman; Ellen P McCarthy Journal: J Clin Oncol Date: 2011-03-14 Impact factor: 44.544
Authors: Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544
Authors: Kevin S Hughes; Lauren A Schnaper; Donald Berry; Constance Cirrincione; Beryl McCormick; Brenda Shank; Judith Wheeler; Lorraine A Champion; Thomas J Smith; Barbara L Smith; Charles Shapiro; Hyman B Muss; Eric Winer; Clifford Hudis; William Wood; David Sugarbaker; I Craig Henderson; Larry Norton Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: Paul L Nguyen; Alphonse G Taghian; Matthew S Katz; Andrzej Niemierko; Rita F Abi Raad; Whitney L Boon; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: Hyunsoon Cho; Carrie N Klabunde; K Robin Yabroff; Zhuoqiao Wang; Angela Meekins; Iris Lansdorp-Vogelaar; Angela B Mariotto Journal: Ann Intern Med Date: 2013-11-19 Impact factor: 25.391
Authors: Erin J Aiello Bowles; Cody Ramin; Diana S M Buist; Heather Spencer Feigelson; Sheila Weinmann; Lene H S Veiga; Clara Bodelon; Rochelle E Curtis; Jacqueline B Vo; Amy Berrington de Gonzalez; Gretchen L Gierach Journal: Breast Cancer Res Treat Date: 2022-03-11 Impact factor: 4.872
Authors: Rachel A Freedman; Anna C Revette; Haley Gagnon; Adriana Perilla-Glen; Molly Kokoski; Saida O Hussein; Erin Leone; Nicole Hixon; Rebeka Lovato; Wendy Loeser; Nancy U Lin; Christina A Minami; Beverly Canin; Barbara LeStage; Meredith Faggen; Philip D Poorvu; Jennifer McKenna; Kathryn J Ruddy; Nancy L Keating; Mara A Schonberg Journal: Breast Cancer Res Treat Date: 2022-07-30 Impact factor: 4.624